QLF 32101
Alternative Names: QLF-32101Latest Information Update: 13 Sep 2024
At a glance
- Originator Qilu Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acute myeloid leukaemia; Myelodysplastic syndromes
Most Recent Events
- 13 Jun 2024 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in China (IV) prior to June 2024 (NCT05703204)
- 13 Jun 2024 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in China (SC) prior to June 2024 (NCT05703204)
- 13 Jun 2024 Phase-I clinical trials in Myelodysplastic syndromes (Second-line therapy or greater) in China (IV) prior to June 2024 (NCT05703204)